Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Pharvaris N.V. has received a consensus recommendation of "Moderate Buy" from six analysts, with an average 12-month price target of $35.60.
• Several large investors have recently increased their stakes in Pharvaris, indicating growing institutional interest in the company.
• Pharvaris reported a quarterly loss of ($0.94) earnings per share, missing analysts' expectations, and is currently trading with a market capitalization of $1.21 billion.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $35.60.

A number of analysts have commented on the stock. Cantor Fitzgerald reduced their price objective on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Guggenheim assumed coverage on shares of Pharvaris in a research report on Wednesday, June 11th. They issued a "buy" rating and a $32.00 price target for the company. Zacks Research raised shares of Pharvaris from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. Wedbush reissued an "outperform" rating and issued a $27.00 price target on shares of Pharvaris in a research report on Thursday, June 5th. Finally, JMP Securities reduced their price target on shares of Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a research report on Wednesday, August 13th.

Pharvaris Stock Down 1.8%

Shares of NASDAQ:PHVS traded down $0.42 on Monday, reaching $22.43. 95,390 shares of the company's stock were exchanged, compared to its average volume of 81,835. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -6.67 and a beta of -2.81. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $26.33. The business's 50-day moving average is $20.82 and its two-hundred day moving average is $17.58.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.07). Analysts predict that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Hedge funds have recently added to or reduced their stakes in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in shares of Pharvaris in the second quarter worth $57,000. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after acquiring an additional 2,847 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Pharvaris during the fourth quarter valued at $64,000. Point72 Asset Management L.P. bought a new position in shares of Pharvaris during the fourth quarter valued at $152,000. Finally, Legal & General Group Plc lifted its holdings in shares of Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after acquiring an additional 994 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.